Overview
Rapt Therapeutics Q3 net loss narrows to $17.6 mln from $18.4 mln in 2024
Company completed $250 mln public offering to strengthen balance sheet
R&D expenses decreased due to lower costs in several areas
Outlook
RAPT plans to report Phase 2 asthma trial results next year
Company to discuss CSU registrational pathway with FDA
RAPT's cash projected to fund operations to mid-2028
Result Drivers
PUBLIC OFFERING - Completed $250 mln public offering to strengthen balance sheet and fund operations to mid-2028
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.65
Q3 Net Income
-$17.58 mln
Q3 Basic EPS
-$0.65
Q3 Operating Expenses
$19.37 mln
Q3 Operating Income
-$19.37 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for RAPT Therapeutics Inc is $60.00, about 52.9% above its November 5 closing price of $28.27
Press Release: ID:nGNX44xBsk
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
